Загрузка...
The efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladder
Mirabegron, is the only β-3 adrenoreceptor (AR) agonist available for the treatment of overactive bladder (OAB). To assess the efficacy and tolerability of this novel drug therapy, two phase II and six phase III Astellas-sponsored trials have been conducted with over 10,500 adults with OAB recruited...
Сохранить в:
| Опубликовано в: : | Ther Adv Urol |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SAGE Publications
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4707426/ https://ncbi.nlm.nih.gov/pubmed/26834839 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287215614237 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|